
  <style>
  .gh-table table { 
    border-collapse: collapse; 
    width: 100%;
    border: 1px solid #444;
    font-size: 12px;
  }
  .gh-table th, .gh-table td { 
    border: 1px solid #444; 
    padding: 4px 6px; 
    vertical-align: top;
    font-weight: 400 !important;   /* regular font */
  }
  .gh-table th { 
    .gh-table th { background: #f5f5f5; text-align: left; }
  }
  .gh-table th { font-weight: 700 !important; }
    @media print {
      .gh-table { font-size: 10px; }
    }
  </style>
  <div class='gh-table'><table><thead><tr><th>record_id</th><th>visit</th><th>Molecola (1)</th><th>Molecola (2)</th><th>description</th></tr></thead><tbody><tr><td>L25</td><td>1</td><td>Acetylsalicylic acid</td><td>Atenolol</td><td>Acetylsalicylic acid may decrease the antihypertensive activities of Atenolol.</td></tr><tr><td>L25</td><td>1</td><td>Cobicistat</td><td>Atenolol</td><td>The metabolism of Atenolol can be decreased when combined with Cobicistat.</td></tr><tr><td>L25</td><td>1</td><td>Cobicistat</td><td>Doxazosin</td><td>The metabolism of Doxazosin can be decreased when combined with Cobicistat.</td></tr><tr><td>L25</td><td>1</td><td>Cobicistat</td><td>Lercanidipine</td><td>The metabolism of Lercanidipine can be decreased when combined with Cobicistat.</td></tr><tr><td>L25</td><td>1</td><td>Darunavir</td><td>Atenolol</td><td>The metabolism of Atenolol can be decreased when combined with Darunavir.</td></tr><tr><td>L25</td><td>1</td><td>Darunavir</td><td>Doxazosin</td><td>The metabolism of Doxazosin can be decreased when combined with Darunavir.</td></tr><tr><td>L25</td><td>1</td><td>Darunavir</td><td>Gliclazide</td><td>The therapeutic efficacy of Gliclazide can be decreased when used in combination
with Darunavir.</td></tr><tr><td>L25</td><td>1</td><td>Darunavir</td><td>Lercanidipine</td><td>The serum concentration of Lercanidipine can be increased when it is combined
with Darunavir.</td></tr><tr><td>L25</td><td>1</td><td>Darunavir</td><td>Metformin</td><td>The therapeutic efficacy of Metformin can be decreased when used in combination
with Darunavir.</td></tr><tr><td>L25</td><td>1</td><td>Darunavir</td><td>Pantoprazole</td><td>The metabolism of Pantoprazole can be decreased when combined with Darunavir.</td></tr><tr><td>L25</td><td>1</td><td>Doxazosin</td><td>Acetylsalicylic acid</td><td>Acetylsalicylic acid may decrease the antihypertensive activities of Doxazosin.</td></tr><tr><td>L25</td><td>1</td><td>Doxazosin</td><td>Atenolol</td><td>Atenolol may increase the orthostatic hypotensive activities of Doxazosin.</td></tr><tr><td>L25</td><td>1</td><td>Emtricitabine</td><td>Metformin</td><td>The excretion of Emtricitabine can be decreased when combined with Metformin.</td></tr><tr><td>L25</td><td>1</td><td>Gliclazide</td><td>Acetylsalicylic acid</td><td>The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid
is combined with Gliclazide.</td></tr><tr><td>L25</td><td>1</td><td>Gliclazide</td><td>Atenolol</td><td>The therapeutic efficacy of Gliclazide can be increased when used in combination
with Atenolol.</td></tr><tr><td>L25</td><td>1</td><td>Gliclazide</td><td>Doxazosin</td><td>The metabolism of Gliclazide can be decreased when combined with Doxazosin.</td></tr><tr><td>L25</td><td>1</td><td>Gliclazide</td><td>Levothyroxine</td><td>The therapeutic efficacy of Gliclazide can be decreased when used in combination
with Levothyroxine.</td></tr><tr><td>L25</td><td>1</td><td>Irbesartan</td><td>Acetylsalicylic acid</td><td>The risk or severity of renal failure, hyperkalemia, and hypertension can be
increased when Irbesartan is combined with Acetylsalicylic acid.</td></tr><tr><td>L25</td><td>1</td><td>Irbesartan</td><td>Atenolol</td><td>Atenolol may increase the hypotensive activities of Irbesartan.</td></tr><tr><td>L25</td><td>1</td><td>Irbesartan</td><td>Doxazosin</td><td>The metabolism of Doxazosin can be decreased when combined with Irbesartan.</td></tr><tr><td>L25</td><td>1</td><td>Irbesartan</td><td>Gliclazide</td><td>The metabolism of Gliclazide can be decreased when combined with Irbesartan.</td></tr><tr><td>L25</td><td>1</td><td>Irbesartan</td><td>Levothyroxine</td><td>The metabolism of Irbesartan can be decreased when combined with Levothyroxine.</td></tr><tr><td>L25</td><td>1</td><td>Lercanidipine</td><td>Acetylsalicylic acid</td><td>Acetylsalicylic acid may decrease the antihypertensive activities of
Lercanidipine.</td></tr><tr><td>L25</td><td>1</td><td>Lercanidipine</td><td>Atenolol</td><td>Atenolol may increase the arrhythmogenic activities of Lercanidipine.</td></tr><tr><td>L25</td><td>1</td><td>Lercanidipine</td><td>Doxazosin</td><td>Lercanidipine may increase the hypotensive activities of Doxazosin.</td></tr><tr><td>L25</td><td>1</td><td>Lercanidipine</td><td>Gliclazide</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Gliclazide.</td></tr><tr><td>L25</td><td>1</td><td>Lercanidipine</td><td>Irbesartan</td><td>Lercanidipine may increase the hypotensive activities of Irbesartan.</td></tr><tr><td>L25</td><td>1</td><td>Lercanidipine</td><td>Metformin</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Metformin.</td></tr><tr><td>L25</td><td>1</td><td>Lercanidipine</td><td>Potassium chloride</td><td>Potassium chloride may increase the hyperkalemic activities of Lercanidipine.</td></tr><tr><td>L25</td><td>1</td><td>Levothyroxine</td><td>Acetylsalicylic acid</td><td>The therapeutic efficacy of Levothyroxine can be increased when used in
combination with Acetylsalicylic acid.</td></tr><tr><td>L25</td><td>1</td><td>Levothyroxine</td><td>Atenolol</td><td>The therapeutic efficacy of Levothyroxine can be decreased when used in
combination with Atenolol.</td></tr><tr><td>L25</td><td>1</td><td>Metformin</td><td>Acetylsalicylic acid</td><td>The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid
is combined with Metformin.</td></tr><tr><td>L25</td><td>1</td><td>Metformin</td><td>Atenolol</td><td>The serum concentration of Metformin can be increased when it is combined with
Atenolol.</td></tr><tr><td>L25</td><td>1</td><td>Metformin</td><td>Levothyroxine</td><td>The therapeutic efficacy of Metformin can be decreased when used in combination
with Levothyroxine.</td></tr><tr><td>L25</td><td>1</td><td>Metformin</td><td>Pantoprazole</td><td>Pantoprazole may decrease the excretion rate of Metformin which could result in
a higher serum level.</td></tr><tr><td>L25</td><td>1</td><td>Metformin</td><td>Potassium chloride</td><td>Metformin may decrease the excretion rate of Potassium chloride which could
result in a higher serum level.</td></tr><tr><td>L25</td><td>1</td><td>Pantoprazole</td><td>Acetylsalicylic acid</td><td>Acetylsalicylic acid may decrease the excretion rate of Pantoprazole which could
result in a higher serum level.</td></tr><tr><td>L25</td><td>1</td><td>Pantoprazole</td><td>Doxazosin</td><td>The metabolism of Doxazosin can be decreased when combined with Pantoprazole.</td></tr><tr><td>L25</td><td>1</td><td>Pantoprazole</td><td>Gliclazide</td><td>The metabolism of Gliclazide can be decreased when combined with Pantoprazole.</td></tr><tr><td>L25</td><td>1</td><td>Pantoprazole</td><td>Levothyroxine</td><td>Pantoprazole can cause a decrease in the absorption of Levothyroxine resulting
in a reduced serum concentration and potentially a decrease in efficacy.</td></tr><tr><td>L25</td><td>1</td><td>Pantoprazole</td><td>Potassium chloride</td><td>Pantoprazole may decrease the excretion rate of Potassium chloride which could
result in a higher serum level.</td></tr><tr><td>L25</td><td>1</td><td>Potassium chloride</td><td>Acetylsalicylic acid</td><td>Potassium chloride may increase the hyperkalemic activities of Acetylsalicylic
acid.</td></tr><tr><td>L25</td><td>1</td><td>Potassium chloride</td><td>Atenolol</td><td>Potassium chloride may increase the hyperkalemic activities of Atenolol.</td></tr><tr><td>L25</td><td>1</td><td>Potassium chloride</td><td>Irbesartan</td><td>Potassium chloride may increase the hyperkalemic activities of Irbesartan.</td></tr><tr><td>L25</td><td>1</td><td>Tenofovir alafenamide</td><td>Acetylsalicylic acid</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Acetylsalicylic acid.</td></tr><tr><td>L25</td><td>1</td><td>Tenofovir alafenamide</td><td>Doxazosin</td><td>The metabolism of Tenofovir alafenamide can be decreased when combined with
Doxazosin.</td></tr><tr><td>L25</td><td>1</td><td>Tenofovir alafenamide</td><td>Irbesartan</td><td>The metabolism of Tenofovir alafenamide can be decreased when combined with
Irbesartan.</td></tr><tr><td>L25</td><td>1</td><td>Tenofovir alafenamide</td><td>Levothyroxine</td><td>The serum concentration of Tenofovir alafenamide can be decreased when it is
combined with Levothyroxine.</td></tr><tr><td>L25</td><td>1</td><td>Tenofovir alafenamide</td><td>Metformin</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Metformin.</td></tr><tr><td>L25</td><td>1</td><td>Tenofovir alafenamide</td><td>Pantoprazole</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Pantoprazole.</td></tr><tr><td>L25</td><td>1</td><td>Tenofovir alafenamide</td><td>Potassium chloride</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Potassium chloride.</td></tr></tbody></table></div>
